logo-loader
viewCellmid Limited

Cellmid supports autoimmune disease treatment with European patent

Cellmid has set up a springboard for the commercial development of a novel autoimmune disease treatment method with the grant of a new European patent.

au_europe_map350_565cf61571e23.jpg

Cellmid (ASX:CDY)  has added an important layer of intellectual property protection with the grant of a European patent for treating autoimmune disorders using midkine inhibitors.

The patent covers the use of midkine inhibitors where the increase of regulatory T cells (Tregs) may be beneficial for treatment, such as multiple sclerosis.

Midkine is a protein that is emerging as an important new target for drug development in the treatment of a number of diseases.

The new patent forms the basis for the commercial development of Cellmid’s midkine antibodies in autoimmune disease indications.

Autoimmune attacks can be mitigated by boosting Treg numbers through the use of midkine antibodies.

In animal models of autoimmunity, inhibiting MK using Cellmid’s MK antibodies alleviated disease.

The new European patent for this method is the third member of the patent family for Cellmid.

The U.S. patent was granted in 2012 and the Japanese patent was granted in 2013.

The patents in this family expire in 2027.


Midkine program

Cellmid’s first-in-class antibodies program includes development of the drug CAB102, which has been demonstrated in formal tests to be a ground breaking method of targeting midkine.

Earlier this year, the company entered into a research and development loan agreement to receive A$1 million for the program.

Recent work across Cellmid’s midkine portfolio has also included the following:

- The company commenced its preclinical collaboration with Complutense University of Madrid, Spain to explore therapeutic opportunities for CAB102, as co-therapy with existing drugs, in glioblastoma.

- The appointment of Dr Bryce Vissel as Chairman of the Scientific Advisory Board triggered fresh activities around the midkine portfolio, including opening negotiations for new collaborations.

- Assay development for the planned human clinical studies has continued during the quarter following the results of the single dose toxicity studies.

- The company’s CAB102 antibody is currently in stability testing prior to multidose toxicity studies.

- Midkine diagnostic collaborations continue to deliver new data in cancer and kidney disease supporting existing collaborations and new license opportunities.


More patent success


Grant of the European patent for midkine treatment of autoimmune disorders follows quickly on the grant of a Japanese patent covering the use of midkine for hair growth treatment.

This patent encompasses the use of this technology in shampoos, conditioners, creams and lotions until 2031.

The new Japanese patent is the third member of Cellmid’s midkine patent family for hair growth to be accepted, following the granting of the UK and Australian patents.

Other patents are filed or are under examination in the U.S., Europe, China, Hong Kong and Korea.

This patent family adds to the already considerable intellectual property assets of Cellmid’s wholly owned anti-aging hair growth subsidiary, Advangen, which includes patent protection and extensive knowhow around its FGF5 inhibiting technologies, cell based assays, formulations and brands.

FGF5 is a protein associated with hair loss.


Analysis

The grant of a European patent for Cellmid’s midkine-based treatment of autoimmune disorders further underpins the prospectivity of the commercial development of this intellectual property.

It also geographically diversifies the company’s push to develop the technology following the grant of similar patents in the U.S. and Japan in recent years.

This development can likewise be interpreted as a broader reinforcement of the strength of Cellmid’s midkine portfolio, which includes work in cancer diagnostics and hair growth/anti-ageing treatments.

As such, Cellmid grants are effective in protecting rights to this portfolio of intellectual property assets while also adding value over time.

Cellmid patents for the use of midkine in hair growth have now been granted in Japan, Australia and the UK.

The company’s 175% jump in cash holdings over the three months to September to A$4.4 million is expected to underpin increased marketing and advertising efforts as these products continue to penetrate new markets.

The company’s latest patents, its dramatic 320% year-on-year increase in sales receipts and its strong investor support in the form of an oversubscribed $4 million placement have all signalled important progress in business development.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Cellmid Limited

Price: 0.12 AUD

ASX:CDY
Market: ASX
Market Cap: $15.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

4 min read